Hansa Biopharma AB Stock Nasdaq Stockholm
Equities
SE0002148817
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
28.47 SEK | -82.57% | -5.78% | -38.73% |
Apr. 18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
Apr. 18 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 239M 22.01M | Sales 2025 * | 343M 31.53M | Capitalization | 1.55B 142M |
---|---|---|---|---|---|
Net income 2024 * | -735M -67.63M | Net income 2025 * | -712M -65.51M | EV / Sales 2024 * | 8.46 x |
Net Debt 2024 * | 474M 43.61M | Net Debt 2025 * | 733M 67.48M | EV / Sales 2025 * | 6.66 x |
P/E ratio 2024 * |
-2.44
x | P/E ratio 2025 * |
-2.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 18-03-19 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | Nov. 30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 20-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Anders Pedersen
BRD | Director/Board Member | 73 | 18-05-28 |
Peter Nicklin
CHM | Chairman | 61 | 22-06-29 |
Mats Blom
BRD | Director/Board Member | 59 | 19-05-21 |
1st Jan change | Capi. | |
---|---|---|
-0.02% | 42.11B | |
+46.34% | 40.08B | |
+5.04% | 40B | |
-11.32% | 26.87B | |
+5.25% | 24.58B | |
-23.83% | 18.44B | |
-1.62% | 11.94B | |
+22.75% | 11.66B | |
+6.44% | 11.01B |